Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 13/20 | 0.52 |
| ▸ | MGLL | Q99685 | 1/20 | 0.51 |
| ▸ | FAAH | O00519 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.47 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29650137 | 1.00 | GPR119 (0.52) | GPR119MGLLFAAHHDAC1CHEK2 | |
| SCHEMBL30485980 | 0.91 | GPR119 (0.49) | GPR119MGLLFAAHIRAK4 | |
| SCHEMBL27226467 | 0.86 | GPR119 (0.61) | GPR119MGLL | |
| SCHEMBL3397468 | 0.86 | FAAH (0.50) | GPR119FAAHHDAC1CHEK2 | |
| SCHEMBL29039936 | 0.85 | FAAH (0.49) | GPR119FAAHHDAC1CHEK2 | |
| SCHEMBL31490060 | 0.84 | HDAC1 (0.49) | GPR119FAAHHDAC1CHEK2 | |
| SCHEMBL17700854 | 0.84 | HDAC1 (0.49) | GPR119FAAHHDAC1CHEK2 | |
| SCHEMBL24493394 | 0.83 | GPR119 (0.46) | GPR119MGLLIRAK4 | |
| SCHEMBL30578231 | 0.83 | GPR119 (0.46) | GPR119MGLLIRAK4 | |
| SCHEMBL29650101 | 0.83 | SLC2A1 (0.49) | GPR119FAAHHDAC1CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240059691-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2024-02-22 | — | — | US | disclosed |
| EP-4255900-A2 | ENZYME INHIBITORS | Kalvista Pharmaceuticals Limited (GB) | 2023-10-11 | — | — | EP | disclosed |
| CN-116745278-A | Enzyme inhibitors | 卡尔维斯塔制药有限公司 | 2023-09-12 | — | — | CN | disclosed |
| CN-116462661-A | Deuterated 3- (pyridin-4-yl) propionic acid compound, and preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2023-07-21 | — | — | CN | disclosed |
| WO-2022118016-A2 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2022-06-09 | — | — | WO | disclosed |
| WO-2022118016-A2 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2022-06-09 | — | — | WO | disclosed |
| EP-3031799-B1 | AROMATIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2018-04-04 | — | — | EP | disclosed |
| US-9776962-B2 | Aromatic compounds with GPR40 agonistic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-10-03 | — | — | US | disclosed |
| EP-3031799-A1 | AROMATIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-06-15 | — | — | EP | disclosed |
| US-20160115128-A1 | AROMATIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160115128-A1 | AROMATIC COMPOUND | GLP1R, GPR119, GPR39 | GPR119 2/4885MGLL 932/4885FAAH 3025/4885 |
| US-20240059691-A1 | ENZYME INHIBITORS | SERPINB1, XDH, ACE | GPR119 1423/4885MGLL 914/4885FAAH 605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.